Zenodo (CERN European Organization for Nuclear Research)
July 8, 2026
Schüller Thomas
The paper presents a political-economic case analysis of work by Abrahms et al. (2026) on CRISPR-associated transposases and psilocybin/DMT production in E. coli, examining how a 'supply framing' in science communication shapes discourse around microbial psychedelic production. It uses the verified case as a domain instance within a broader research framework, arguing that the supply narrative appropriates and frames non-scarce resources.
Zenodo (CERN European Organization for Nuclear Research)
July 8, 2026
Schüller Thomas
Two works examine the appropriation of Indigenous healing practices. The first, 'Die enteignete Heilerin' (The Expropriated Healer), focuses on the Mazatec shaman Maria Sabina, whose use of psilocybin mushrooms was co-opted by outsiders. The second, 'Vier Enteignungen, ein Muster' (Four Expropriations, One Pattern), compares the appropriation of peyote, ayahuasca, salvia, and iboga, arguing that a common pattern of colonial and capitalist expropriation underlies these cases.
Zenodo (CERN European Organization for Nuclear Research)
July 8, 2026
Schüller Thomas
This work presents a transdisciplinary analysis comparing the effects of whole-mushroom preparations (Ganzpilz) with isolated psilocybin, focusing on the entourage effect—the idea that natural compounds work synergistically. The argument suggests that whole-mushroom matrices may produce different experiential or therapeutic outcomes than psilocybin alone, challenging reductionist approaches in psychedelic research. The text outlines a theoretical framework for understanding how secondary compounds modulate psilocybin's effects, though no empirical data or specific findings are reported.
Zenodo (CERN European Organization for Nuclear Research)
July 1, 2026
Schüller Thomas
DMT is the fourth classical psychedelic in a series and has five distinguishing features: oral inactivity without an MAO inhibitor; ultra-short duration (minutes) when smoked or injected; ayahuasca as a plant combination (DMT source plus β-carboline MAOI); endogenous occurrence in mammals; and the unique religious legal ruling Gonzales v. O Centro (2006). Chemically, DMT is a tryptamine (like psilocybin and LSD), contrasting with the phenethylamine mescaline. This bilingual full work provides a transdisciplinary scientific overview of DMT and ayahuasca across eight disciplines, with explicit labeling of levels of certainty (confirmed / probable / open).
Zenodo (CERN European Organization for Nuclear Research)
July 1, 2026
Schüller Thomas
Mescaline is the only phenethylamine among the classic psychedelics, with the lowest affinity for the 5-HT2A receptor, requiring the highest doses (hundreds of milligrams) and producing a dose-dependent duration of 6.4 to 14 hours. Clinical research is the weakest strand: as of 2026, no adequate randomized controlled trial exists. In the ecologically bound case of peyote, the logic of dispossession reverses compared to synthetic substances like LSD and psilocybin. The work elevates Discipline 8 (Law/Society) to address peyote conservation (IUCN 'vulnerable') and Indigenous rights (Native American Church, AIRFA 1994) as a standalone discipline.
Zenodo (CERN European Organization for Nuclear Research)
July 1, 2026
Schüller Thomas
A transdisciplinary monograph examines the cultivated psychoactive mushroom as a case of access reorganization, comparing it with peyote. The work argues that the regulation and cultural framing of these substances reshape who can access them and under what conditions, thereby reorganizing social and legal boundaries. The analysis draws on psychoanalysis and social critique to explore themes of closure, the fall of man, and therapeutic applications. The author presents this as a theoretical and philosophical paper, not an empirical study, and offers a bilingual (German and English) account funded privately and licensed under Creative Commons.
Zenodo (CERN European Organization for Nuclear Research)
June 24, 2026
Schüller Thomas
A tetralogy of four linked scholarly works, grounded in the ρ/δ-Master Theorem, examines the political economy and pharmacology of psychoactive substances. One work traces substance economics from black markets to stock exchange listings, auditing original studies on MDMA, psilocybin, and ketamine. Another analyzes the opioid crisis as a domain instance, covering Purdue/Sackler litigation, pharmacology, toxicology, and three CDC waves. A provisional work examines telemedicine platforms like Cerebral and Done as prescription-dispensing platforms, highlighting regulatory pivots. A second provisional work contrasts stimulants (cocaine, amphetamine, methamphetamine) across pharmaceutical and illegal markets, focusing on the drug/medicine boundary and supply gaps.